If you get a 1% piece of that, that's a $1 billion drug, right?" Small biotech companies make moves Other small drugmakers trying to enter the space include Viking Therapeutics, which is developing drugs that target GLP-1 and another hormone called GIP
Interestingly, the GLP-1 receptor agonist, dulaglutide, and the dual GLP-1 and GIP receptor agonist, tirzepatide, are both characterized by a strong delayed gastric emptying upon a single dose administration, but the effect tends to subside as gastric emptying tachyphylaxis is observed after several weeks of treatment
Feb 3, 2026 Of all the growth hormone secretagogues that have shaped peptide research over the past three decades, GHRP-6 remains the most polarizing
Here, modularity is evident in the diversity of available approaches: mainstream anaerobic treatment, aerobic membrane bioreactors (MBRs), AnMBR, and variants of nutrient removal systems
and excessive excitatory glutamatergic transmission and compromised GABA mediated inhibition (Maletic and Raison, 2009)